EUVIMEDEUVIMED entdecken
Editorial

Targeting residual inflammatory risk: The next frontier for atherosclerosis treatment and prevention

Paul M Ridker

Vascular Pharmacology · 2023-12 · 153 · 107238

DOI: 10.1016/j.vph.2023.107238 ↗

Kurz gefasst

Editorial in der Zeitschrift Vascular Pharmacology, 2023-12. Verfasst von Paul M Ridker. Beteiligte Einrichtung: From the Center for Cardiovascular Disease Prevention, Division of Preventive Medicine and the Division of Cardiovascular Medicine, Brigham and Women…. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammation and hyperlipidemia act synergistically to drive atherosclerotic progression. Multiple randomized trials now demonstrate that "lower is better" not only for LDLC, but also for hsCRP. Recent data among statin treated patients indicates that residual inflammatory risk is a stronger determinant of recurrent events than residual cholesterol risk. Based on trial data demonstrating a 31% reduction in events with minimal side effects, low-dose colchicine (0.5 mg daily) has been approved by the United States Food and Drug Administration to lower rates of myocardial infarction, stroke, and cardiovascular death as an adjunct to statin therapy. Physicians can anticipate novel anti-inflammatory agents in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsAtherosclerosisHumansBiomarkersInflammationC-Reactive Protein

Stichwörter der Autor:innen

AtherosclerosisC-reactive proteinColchicineInflammationInterleukin-6

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsBiomarkersC-Reactive Protein

Autor:innen und Institutionen

  • From the Center for Cardiovascular Disease Prevention, Division of Preventive Medicine and the Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA. Electronic address: pridker@bwh.harvard.…

Zitieren

APA

Ridker, P. M. (2023). Targeting residual inflammatory risk: The next frontier for atherosclerosis treatment and prevention. Vascular Pharmacology, 153, 107238. https://doi.org/10.1016/j.vph.2023.107238

Vancouver

Ridker PM. Targeting residual inflammatory risk: The next frontier for atherosclerosis treatment and prevention. Vascular Pharmacology. 2023;153:107238. doi:10.1016/j.vph.2023.107238

BibTeX
@article{Ridker2023,
  author = {Ridker, Paul M},
  title = {Targeting residual inflammatory risk: The next frontier for atherosclerosis treatment and prevention},
  journal = {Vascular Pharmacology},
  year = {2023},
  volume = {153},
  pages = {107238},
  doi = {10.1016/j.vph.2023.107238}
}
Kostenlos starten →